Exchange: NASDAQ·Updated 07:57 PM EST
FLGT logo

FLGT Fulgent Genetics Inc

$24.12
$0.66
(2.66%)
Today
Closed $24.12
$0.47
(1.95%)
After Hours
Reported EarningsNov 5
Mkt Cap$673.89M
Vol322,991.00

About FLGT

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.
35

Bearish Sentiment

How do you feel about FLGT?

BiotechSwings
27% Friday and $FLGT actually earned it imo Q3 revenue hit 90.4 million, up 8% year over year, and the loss came in at 9 cents vs 65 cents expected pathology did the heavy lifting, up 57% to 40.9 million, and the stock closed at 23.74 they tightened the full year loss guide to 1.65 to 1.75 from 2.22 to 2.35, year end cash guided near 630 million
1
2
Sexydream
$FLGT who's still holding this at 19? Aside from and See? Noone. Everyone's smart enough to leave a junk stock. Cut your losses like I've been telling you since the stock was at $60.
1
Sexydream
$FLGT Will this junk stock EVER have an up year? Down 17% ytd. Every year it's down double digit % while the market keeps making new all time highs. Talk about bag holding and OPPORTUNITY COST.
1
Sexydream
$FLGT what did I tell you idiots! "rally" is over. Now we start our descent back down to 15! Muahahahahah
1
twitweetz
$FLGT interesting on the cc Ming led with therapeutics for the first time. usually it's at the end of his remarks. maybe it's nothing...
1
jf152
$FLGT Future catalysts from earnings call: "We held the end of the Phase 2 meeting with the FDA in August. We look forward to sharing more with you later this year. " "We continue to approach conversations with the partners who bring both resource and strategic alignment."
jf152
Makes a ridiculously false prediction without any justification.... And then likes his own post. $FLGT
StocktwitsEarnings
$FLGT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.09 down -164.29% YoY • Reported revenue of $90.41M up 7.54% YoY • Fulgent Genetics expects its collection rate and corresponding gross margin to improve as remaining billing-system customizations are completed, while research and development expenses are expected to increase as clinical trials progress.

Advertisement|Remove ads.